Showing 1151-1160 of 1317 results for "".
- LEO Pharma Announces Positive Phase 3 Trial Results for Delgocitinib Cream in Adults With Chronic Hand Eczema (CHE)https://practicaldermatology.com/news/leo-pharma-announces-positive-phase-3-trial-results-for-delgocitinib-cream-in-adults-with-chronic-hand-eczema-che/2461556/LEO Pharma announced positive results of the DELTA 2 trial, the second of two pivotal phase 3 clinical trials evaluating delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
- Study Establishes Optimal Drug Delivery Settings for Needle-free Jet Injectorshttps://practicaldermatology.com/news/study-establishes-optimal-drug-delivery-settings-for-needle-free-jet-injectors/2461085/Needle-free jet injectors have been used in dermatological practice for many years for the nearly pain-free transdermal drug delivery for indications such as hypertrophic scars, keloids, and warts, but predefined clinical endpoints that guide physicians to choose optimal device settings have not
- New Research Explores Nanotechnology as a Vehicle for Delivering Cannabinoids in Dermatologyhttps://practicaldermatology.com/news/new-research-explores-nanotechnology-as-a-vehicle-for-delivering-cannabinoids-in-dermatology/2460849/Nanotechnology delivery systems may be an innovative and effective approach to delivering cannabinoids for skin care, according to a team from the Department of Dermatology at the George Washington University School of Medicine and Health Sciences in Washington, DC. Research fellow Naga
- FDA Fast Tracks Leo Pharma’s Delgocitinib Cream for Hand Eczemahttps://practicaldermatology.com/news/fda-fast-tracks-leo-pharmas-delgocitinib-cream-for-hand-eczema/2460490/Delgocitinib cream, Leo Pharma’s investigational topical pan-Janus kinase (JAK)-inhibitor, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of adults with moderate-to-severe chronic hand eczema (CHE). There are curr
- Mode of Delivery at Birth May Shape Child's Skin Microbiomehttps://practicaldermatology.com/news/mode-of-delivery-at-birth-may-shape-childs-skin-microbiome/2460123/New research shows that bacterial genera in children were more similar to those of their own mothers than to those of unrelated women. Their data suggest that the mode of delivery at birth could be an important factor in shaping the child's microbiome. The findings appear in the&nbs
- AAD Honors Dr. Robert Brodell for Establishing Free Clinic in the Mississippi Deltahttps://practicaldermatology.com/news/aad-honors-dr-robert-brodell-for-establishing-free-clinic-in-the-delta/2459998/Robert T. Brodell, MD, FAAD, is an American Academy of Dermatology (AAD) Patient Care Hero for working with colleagues at the University of Mississippi Medical Center in Oxford to open a dermatology clinic in the Delta — an area of the state that previously did not have a dermatologist for
- No Need to Delay Certain Skin Procedures for Isotretinoin Patientshttps://practicaldermatology.com/news/no-need-to-delay-certain-skin-procedures-for-isotretinoin-patients/2458140/New consensus recommendations set the record straight on the timing of skin procedures for patients taking isotretinoin. After reviewing 32 relevant publications, the authors found “insufficient evidence” to support delaying manual dermabrasion, superficial chemical peels
- First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/first-patient-enrolled-in-delivers-study-of-diacerein-1-ointment-for-ebs/2458168/The first patient has enrolled in Castle Creek Pharmaceuticals (CCP) Phase 2/3 DELIVERS clinical trial evaluating the safety and efficacy of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bull
- Take That, Acne: BPX-01 Topical Gel Delivers Minocycline Precisely to the Skinhttps://practicaldermatology.com/news/take-that-acne-bpx-01-topical-gel-delivers-minocycline-precisely-to-the-skin/2458490/BioPharmX Corporation’s novel topical minocycline, BPX-01, may be as effective as its oral counterpart minus the systemic side effects, new research suggests. "These results are promising, that topical minocycline gel delivered as BP
- Cynosure Receives FDA Clearance to Market PicoSure Energy Delivery System for Tattoos and Pigmented Lesionshttps://practicaldermatology.com/news/cynosure-receives-fda-clearance-to-market-picosure-energy-delivery-system-for-tattoos-and-pigmented-lesions/2458554/The FDA granted clearance to Cynosure to market a new Laser Delivery System for PicoSure. Together with the FDA cleared 532nm and 755nm wavelengths, Cynosure's new 1064nm Laser Delivery System improves the multi-wavelength laser technology for removing the full color spectrum of tattoo inks i